Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 34.25 GBp
Change Today 0.00 / 0.00%
Volume 14.1K
FUM On Other Exchanges
As of 11:30 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

futura medical plc (FUM) Snapshot

34.25 GBp
Previous Close
34.25 GBp
Day High
34.25 GBp
Day Low
34.25 GBp
52 Week High
08/26/14 - 58.00 GBp
52 Week Low
01/21/15 - 26.25 GBp
Market Cap
Average Volume 10 Days
-0.03 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for FUTURA MEDICAL PLC (FUM)

Related News

No related news articles were found.

futura medical plc (FUM) Related Businessweek News

No Related Businessweek News Found

futura medical plc (FUM) Details

Futura Medical plc engages in the research and development of pharmaceutical drugs and medical devices in the United Kingdom. The company offers CSD500, a condom that incorporates an erectogenic compound to help men maintain a firmer erection during intercourse whilst wearing a condom; MED2002, a gel applied directly to the penis for the treatment of male erectile dysfunction; and PET500, a topical spray that enables men to prolong their sexual experience. Its pain relief management products, such as TPR100 and TIB200 incorporates a non-steroidal anti-inflammatory drug; and SPR300 a topical gel combines methyl salicylate and menthol. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

7 Employees
Last Reported Date: 03/25/15
Founded in 2001

futura medical plc (FUM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 237.7K GBP
Finance Director, Secretary, Financial Contro...
Total Annual Compensation: 142.1K GBP
Chief Scientific Officer and Adviser to the B...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

futura medical plc (FUM) Key Developments

Futura Medical plc Announces Commencement of MED2002 Clinical Trial

Futura Medical plc announced that it has received all of the regulatory approvals needed to begin its pivotal efficacy trial of MED2002, the company's topical gel for the treatment of erectile dysfunction ("ED"), and that pre-screening of patients has commenced. The design of the trial has been modified to include a larger number of patients, which will increase the statistical robustness of the outcomes from the study. A total of 192 patients are now expected to take part in the trial, which is taking place in the UK in London. The primary end point of the trial is the efficacy of MED2002 in male subjects self-diagnosed with ED using the erectile function domain of the International Index of Erectile Function (IIEF). The IIEF is a well validated measure of erectile function and was used for the approval of PDE5 inhibitors, such as Viagra®. Secondary endpoints in the trial will include the speed of onset. The trial will be of a randomised, placebo-controlled, double blind, home use, crossover design. The increased number of patients means that the study is expected to report in H1 2016, compared with earlier guidance of fourth quarter of 2015. Further recruitment sites within the EU have been identified and, pending satisfactory country specific regulatory and ethical approvals, it may be possible to accelerate patient recruitment and thereby achieve an earlier reporting date. Further updates on the trial's progress will be provided as appropriate. Assuming that this trial is successful, it is expected to be one of two pivotal trials required for the regulatory filing of the product. Futura has received interest from potential commercial partners for MED2002 and the commercialisation strategy, including design of the second pivotal trial, will be decided following the results of the current trial.

Futura Medical plc, Annual General Meeting, Jun 17, 2015

Futura Medical plc, Annual General Meeting, Jun 17, 2015., at 16:00 GMT Standard Time. Location: the offices of Buchanan.

Futura Medical plc Reports Preliminary Group Earnings Results for the Year Ended December 31, 2014

Futura Medical plc reported preliminary earnings results for the year ended December 31, 2014. For the year, the Group reported revenue of £43,929 compared to £370,902, operating loss of £3.5 million compared to £2.5 million, loss before tax of £3.5 million compared to £2.5 million, total comprehensive loss attributable to owners of the parent company of £3.0 million or 3.35 pence per basic and diluted share compared to £2.2 million or 2.85 pence per basic and diluted share, net cash used in operating activities of £3.1 million compared to £2.0 million and purchase of plant and equipment of £7,793 compared to £5,048 for the last year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FUM:LN 34.25 GBp 0.00

FUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FUM.
View Industry Companies

Industry Analysis


Industry Average

Valuation FUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 772.7x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 769.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FUTURA MEDICAL PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at